"You know how the game is played."
"First comes the heavy accumulation as the major brokerages put thier clients in the stock and then the upgrades follow."
"Biodel is the perfect situation for this to occur. Company has no debt, PDUFA date only weeks away, six analysts with an average price target of $15.00, and a new BOD member who is a former ML executive with more than 30 years experience in international acquisitions."
p.s. Shorts have already lost the game and they don't know it yet.
"Game over for the shorts!!!"
GSK needs to replace Avandia. SNY has announced they're looking for several acquisitions in the diabetes drug arena.
Management has stated that they are already in talks with several companies.
Accumulation phase is underway.
Upgrades to follow.
Motley Fool and Cramer jump on the bandwagon.
In the $10.00-$12.00 range prior to the PFUFA date.
SNY/GSK could buy the company at any time. $30.00/share.
Shorts got suckered in on news not related to BIOD in August. How does it feel to be shorting BIOD on unrelated news?? Thats how wall street works. They try to make you place a wrong bet and then watch you try to cover at market price for a major loss.
"Still can't understand why indiviuals are focused on this hitting $6 or $7. They should be thinking $25.00 with approval or $20.oo before the PDUFA date as a buyout candidate."
Just a thought!!!!